Rheumatoid Arthritis: A Chronic Disease
Hours: 1.00
Rheumatoid arthritis (RA) is a chronic autoimmune disorder. It is a systemic inflammatory disease. However, it tends to focus on the body’s connective tissue and joints. This course will give the background and pathophysiology, signs and symptoms, diagnostic criteria, treatment, and other disease considerations for RA.
Rheumatoid arthritis (RA) is a chronic autoimmune disorder. It is a systemic inflammatory disease. However, it tends to focus on the body’s connective tissue and joints. This course will give the background and pathophysiology, signs and symptoms, diagnostic criteria, treatment, and other disease considerations for RA.
California Board of Registered Nursing
Provider approved by the California Board of Registered Nursing, CEP# 13791
Nurses will receive 1.00 contact hours for participating in this course.
District of Columbia Board of Nursing
District of Columbia Board of Nursing Approved Continuing Education program (CEBroker Provider #50-290).
Nurses will receive 1.00 contact hours for participating in this course.
Florida Board of Nursing
Florida Board of Nursing (CEBroker Provider #50-290)
Nurses will receive 1.00 contact hours for participating in this course.
American Nurses Credentialing Center
In support of improving patient care, Relias LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nurses will receive 1.00 Nursing Contact Hours after successfully completing this course.
Georgia Board of Nursing
Georgia Board of Nursing (CEBroker Provider #50-290)
Nurses will receive 1.00 contact hours for participating in this course.
South Carolina Board of Nursing
South Carolina Board of Nursing (CEBroker Provider #50-290)
Nurses will receive 1.00 contact hours for participating in this course.
American Society for Clinical Laboratory Science
Relias LLC is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program.
West Virginia Board of Registered Nursing
West Virginia Board of Registered Nursing (CEBroker Provider #50-290)
Nurses will receive 1.00 contact hours for participating in this course.
New Mexico Board of Nursing
New Mexico Board of Nursing (CEBroker Provider #50-290)
Nurses will receive 1.00 contact hours for participating in this course.
Arkansas State Board of Nursing
Arkansas State Board Of Nursing Approved Continuing Education program (CEBroker Provider #50-290).
Nurses will receive 1.00 contact hours for participating in this course.
Tennessee Medical Laboratory Board
Tennessee Medical Laboratory Board (CEBroker Provider #50-290)
Kentucky Board of Nursing
Kentucky Board of Nursing (CEBroker Provider #50-290)
Nurses will receive 1.00 contact hours for participating in this course.
Mississippi Board of Nursing
Mississippi Board of Nursing (CEBroker Provider #50-290)
Nurses will receive 1.00 contact hours for participating in this course.
North Dakota Board of Nursing
North Dakota Board of Nursing (CEBroker Provider #50-290)
Nurses will receive 1.00 contact hours for participating in this course.
Louisiana Board of Medical Examiners- Clinical Laboratory Personnel
Louisiana Board of Medical Examiners - Clinical Laboratory Personnel (CEBroker Provider #50-290)
Michigan Board of Nursing
Michigan Board of Nursing (CEBroker Provider #50-290)
Nurses will receive 1.00 contact hours for participating in this course.
Wyoming Board of Nursing
Wyoming Board of Nursing (CEBroker Provider #50-290)
Nurses will receive 1.00 contact hours for participating in this course.
Kansas State Board of Nursing
Kansas State Board of Nursing (CEBroker Provider #50-290)
Nurses will receive 1.00 contact hours for participating in this course.
Review the epidemiology and pathophysiology of RA.
Recall symptoms and diagnostic criteria for RA.
Identify appropriate treatments and other considerations for patients with RA.
Outline:
Section 1: Introduction
About This Course
Learning Objectives
Section 2: Overview
Meet Sylvia
Background
Epidemiology
Pathophysiology
Key Takeaways
Section 3: Diagnosis
Symptoms and General Diagnostic Overview
ACR-EULAR Diagnostic Criteria
Labs
Imaging
Key Takeaways
Section 4: Treatment Considerations
Overview
NSAIDs
Steroids
Immunosuppressive Agents
csDMARDs
bDMARDS (Biologics)
tsDMARDS (Biologics)
IVIG or SCIG
Diet
Physical and Occupational Therapy
Section 5: Other Considerations
Macrophage Activation Syndrome (MAS)
Vaccines and Preventative Measures
Quality of Life and Coping
Section 6: Clinical Vignette
Section 7: Conclusion
Course Summary
Course Contributor
Resources
References
Subject Matter Expert: Shalla Newton, MSN, RN, NE-BC
Shalla is a subject matter expert (SME)/writer for Relias. She completed her BSN and two undergraduate degrees with top honors from the University of Wisconsin-Madison. Shalla earned her dual MSN degrees from Johns Hopkins University with top honors. She also maintains her post-baccalaureate nurse educator certificate (NE-BC). Shalla’s tenure spans over 20 years of cross-functional leadership and direct clinical roles in healthcare, biopharma/biotech, government affairs, managed care/market access, nonprofit patient advocacy, and research. Her subject matter expertise is in rare, orphan, and complex diseases. Her sub-expertise is in immune-mediated diseases (rheumatology and immunology), genetics, neurology, hematology/oncology, several pediatric diseases, population/public health, and larger systemic healthcare affairs. Shalla is a published author with leading rare disease experts and a global speaker. She also sits on scientific, advocacy, and legislative advisory boards. She has led national advocacy and disease awareness campaigns, including speaking before congress, leading to the first-in-class rare disease biologic approval and investigative treatment protocols.
Disclosure: Shalla Newton, MSN, RN, NE-BC has no Relevant Financial or Non-Financial Relationship with ineligible companies to disclose.
The target audience for this course is: Clinical Laboratory Personnel; Nurses; in the following settings: Acute Care Facility.
Asynchronous/Online Distance Learning; please see certificate details for specifics on delivery format.
Relias has a grievance policy in place to facilitate reports of dissatisfaction. Relias will make every effort to resolve each grievance in a mutually satisfactory manner. In order to report a complaint or grievance please contact Relias.
If you require special accommodations to complete this module, please contact Relias Support by completing the web form (https://www.relias.com/help) or by using the chat functionality.
All courses offered by Relias, LLC are developed from a foundation of diversity, inclusiveness, and a multicultural perspective. Knowledge, values and awareness related to cultural competency are infused throughout the course content.
Reference herein to any specific commercial product, process, or service by trade name, trademark, service mark, manufacturer or otherwise does not constitute or imply any endorsement, recommendation, or favoring of, or affiliation with, Relias, LLC.
All characteristics and organizations referenced in the following training are fictional. Any resemblance to any actual organizations or persons living or dead, is purely coincidental.
To earn continuing education credit for this course you must achieve a passing score of 80% on the post-test and complete the course evaluation.
If you require special accommodations to complete this module, please contact Relias Customer Support here.
